Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the com ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an ‘Overweight’ rating on the stock with a $145 price target.

Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

That number works out to 52.7% of SLNO's average daily trading volume over the past month, of 665,610 shares. Particularly high volume was seen for the $90 strike call option expiring July 18, ...

REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...